Algorithms for the automated selection of fragment-like molecules using single-point surface plasmon resonance measurements.

Fragment-based approaches have added to the arsenal of tools used to identify novel developable leads for drug discovery with high ligand efficiencies. A variety of label-free technologies have been developed and used throughout the industry for fragment screening. Using surface plasmon resonance (SPR) as a fragment screening platform is a relatively new approach. The miniaturization and automation of this technology has led to an associated problem: the large volume of raw data often makes it challenging to analyze and integrate the results of SPR data into the workflow of project teams engaged in the discovery process in a timely fashion. As such, several sets of equations were derived and implemented on Merck's intranet to score single sensorgrams to distinguish stable binders from weak or anomalous binders. This set of equations was optimized and validated on simulated data to both capture "fragment-like" behavior from SPR experiments and filter out much of the anomalous behavior commonly observed. It has subsequently been applied successfully to several in-house discovery programs.

[1]  Allen B Reitz,et al.  Hit triage using efficiency indices after screening of compound libraries in drug discovery. , 2009, Current topics in medicinal chemistry.

[2]  Andrew R. Leach,et al.  Molecular Complexity and Its Impact on the Probability of Finding Leads for Drug Discovery , 2001, J. Chem. Inf. Comput. Sci..

[3]  M. Verdonk,et al.  Structure-guided fragment screening for lead discovery. , 2004, Current opinion in drug discovery & development.

[4]  Paul G Wyatt,et al.  Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design. , 2008, Journal of medicinal chemistry.

[5]  Christopher L. McClendon,et al.  Reaching for high-hanging fruit in drug discovery at protein–protein interfaces , 2007, Nature.

[6]  Walter Huber,et al.  Fragment-Based Screening Using Surface Plasmon Resonance Technology , 2009, Journal of biomolecular screening.

[7]  Lorenz M Mayr,et al.  Novel trends in high-throughput screening. , 2009, Current opinion in pharmacology.

[8]  Christopher I. Bayly,et al.  Evaluating Virtual Screening Methods: Good and Bad Metrics for the "Early Recognition" Problem , 2007, J. Chem. Inf. Model..

[9]  M. Congreve,et al.  A 'rule of three' for fragment-based lead discovery? , 2003, Drug discovery today.

[10]  Michèle N Schulz,et al.  Recent progress in fragment-based lead discovery. , 2009, Current opinion in pharmacology.

[11]  T Neumann,et al.  SPR-based fragment screening: advantages and applications. , 2007, Current topics in medicinal chemistry.

[12]  Edgar Jacoby,et al.  Library design for fragment based screening. , 2005, Current topics in medicinal chemistry.

[13]  E. Fluder,et al.  Protocols for Bridging the Peptide to Nonpeptide Gap in Topological Similarity Searches. , 2001 .

[14]  U Helena Danielson,et al.  Fragment library screening and lead characterization using SPR biosensors. , 2009, Current topics in medicinal chemistry.

[15]  P. Hajduk.  Fragment-based drug design: how big is too big? , 2006, Journal of medicinal chemistry.

[16]  Joseph C. Lin.  Rule of Three: a case of discrimination against certain authors caused by the cataloging rules , 1985 .

[17]  M. Uesugi,et al.  [Discovering high-affinity ligands for proteins: SAR by NMR]. , 2007, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme.

[18]  Anthony M Giannetti,et al.  Surface plasmon resonance based assay for the detection and characterization of promiscuous inhibitors. , 2008, Journal of medicinal chemistry.